These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
3. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related]
4. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951 [TBL] [Abstract][Full Text] [Related]
5. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098 [TBL] [Abstract][Full Text] [Related]
6. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer. Schneider J; Philipp M; Salewski L; Velcovsky HG Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474 [TBL] [Abstract][Full Text] [Related]
7. The diagnostic and prognostic value of ProGRP in lung cancer. Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442 [TBL] [Abstract][Full Text] [Related]
8. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cyfra 21-1 as a marker for lung cancer. Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188 [TBL] [Abstract][Full Text] [Related]
10. [Tumor markers in lung cancer]. Niho S; Shinkai T Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391 [TBL] [Abstract][Full Text] [Related]
11. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer. Oremek GM; Sapoutzis N Anticancer Res; 2003; 23(2A):895-8. PubMed ID: 12820319 [TBL] [Abstract][Full Text] [Related]
12. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320 [TBL] [Abstract][Full Text] [Related]
13. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. Miyake Y; Kodama T; Yamaguchi K Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119 [TBL] [Abstract][Full Text] [Related]
14. ProGRP: a new biomarker for small cell lung cancer. Molina R; Filella X; Augé JM Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231 [TBL] [Abstract][Full Text] [Related]
15. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660 [TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer]. Yang J; Li R; Li A Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234 [TBL] [Abstract][Full Text] [Related]
17. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424 [TBL] [Abstract][Full Text] [Related]
18. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815 [TBL] [Abstract][Full Text] [Related]
19. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics. Bubanović G; Pavićević R; Franjević A Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223 [TBL] [Abstract][Full Text] [Related]
20. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]